Proventis Partners advised opTricon

Chembio and the shareholders of privately held opTricon GmbH have signed an agreement to acquire 100% of the shares in opTricon GmbH.

Founded in Berlin in 2005, opTricon Entwicklungsgesellschaft für optische Technologien mbH develops and produces optical system solutions for medical engineering and diagnostics applications.

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. Chembio’s products are sold globally, directly and through distributors, to hospitals, physician offices, clinical laboratories, public heal organizations and government agencies.

Proventis Partners advised the shareholders and opTricon GmbH during all phases of the cross-border transaction. The scope of the project included the advice during the early commercial negotiations up to the management of the entire sale process of the company to a US-listed buyer in a market environment with demanding regulatory and IP requirements.